Plenary Session - inactive due to federal service

Early treatment of myeloma, dual vs. single maintenance, and finally transplant or no transplant.

Why the USPSTF is wrong

Cost of Cancer drugs - VP's lecture

I combine two latest tracks on interpreting medical studies, medical boards, 7 doses of vaccine, and finally Walensky. Stay tuned.

We explore the fight btw NYTimes, Cochrane, and the last people keeping EBM alive

Zeb joins me for the 7th time to discuss all the key pandemic questions

My lecture to Harvard regulatory science

VP goes to Denmark to give the keynote at the Danish medical association conference

What is science?

Karmma 3 discussion; then Sensible Medicine on Long COVID, 4th year fellowships and more; Then my breakdown of FDA's NEJM Letter to the Editor

I get into endpoints, surrogates, validation, blinding, crossover, and control arms.

I talk RCTs 101; KM Plots; Blinding: 2:1 randomization: Concealment and more. Then Papa Heme Tells you How to Find your First Job

Dr. Tom Newman UCSF Emeritus Professor & Superb teacher discusses VP's recent Public Health Videos. The two don't fully agree, but the discussion is worth your time.

Mike Putman, asst prof. EBM Rhematologist debates me on value of boosters, observational studies and more.

A new podcast feed called Sensible Medicine is up; here is a sample of what we have to offer

I destroy the trial. Bad control arm. Informative Censoring. No OS gain. Authors DOWNPOWERED TRIAL. Fishy PFS. Fishy HRQoL. This trial should be in trash can.

I annotate an online case discussion; Every decision is not based in evidence. Madness

This lecture on Burnout will not be like any other you have heard

I break down the GEM CESAR trial K, R, D, Pom, Dara, Dex, R, and Auto and all before you actually have cancer What a crazy trial!

This uncontrolled trial of Dara-KRD claims to be looking for cure; Unfortunately, the PI has not thought through what that would look like, and accordingly all the claims are incorrect. Moreover the primary endpt is negative. Sad day for oncology

Sample size games, primary endpoint, head to head trials in oncology Rate this podcast on itunes Coming next is Triangle trial

Grand rounds on heme and heme malignancies given 12/16 at University of Southern California (some parts removed) More ASH coming soon

Is it acceptable to take someone with myeloma who has gotten just 2 regimens and put them on a phase 1? VP says hell no.

In this lecture given December 7, 2022, I cover 5 things: Vaccines Masking Long COVID Schools/Immunity Debt Paxlovid

Should we treat smoldering MM, a debate Long COVID vs Long URI Review the show; Say Hi at ASH22

Smart Start is a useless lymphoma study; We have to stop putting our careers ahead of patients. In the second part, I discuss the 'experts' featured on STAT. Wowzers. I will be at ask. Hit me up: [email protected]

I am joined by Cornell Professor Paul Fenyves; a practicing internist Dr. Fenyves walks us through COVID19 policy. We will be back soon with more cancer medicine. Including a devastating lymphoma one.

I was invited to give this talk to a UK conference on Myeloma Please LEAVE A REVIEW of this podcast

Lecture I gave this weekend in Hawaii to the Medical Oncology Association; One of the best audiences I've had

I give Grand Rounds to UCSF Neurosurgery on how to read and interpret Neurosurgery Studies (Video and slides coming soon to YouTube) Also I discuss Bob Califf's Promotion of Paxlovid

Learning Loss is Devastating; Here are the data and what it means

Learn about UCSF Hematology Oncology Program with Dr. Gerald Hsu, MD PhD Malignant Heme and Program Director

A new study from Switzerland confirms the rate of subclinical myocarditis

LONG COVID, Vaccines, Paxlovid and More

discuss NordICC with the trial PI Power calc specified 50% non-adherence ADR is on par with US studies from the time Colo quality good Perf rate lower than US! How does he counsel individuals & governments What he thinks of USPSTF

A double standard to condemn data with limitations, based on political party, will destroy medicine. We will back to oncology soon, but this is important

Cifu, Mandrola and Prasad fight about colonoscopy

I break down the history and data for the first ever randomized trial of colonoscopy, appearing in NEJM on Oct 9, 2022

Polo Javelin 100 bladder Crossover Control arms How to read and keep up with the literature

Invited Lecture to Cancer Center Directors

I travel to UCSD to interview Dr. Goodman about myeloma, celebrity oncology culture, his career, education, patient care, choosing a specialty and more.

Based on listener questions, I discuss how to apply for and get your first job.

T.O. joins me for the missing episode. These are the unspoken rules of Oncology; We dive deeper into Malignant Book Club.

Timothee Olivier joins me for the 7th installment of our book-club We cover famous trials in oncology

How do careers vary between the academy and industry? We have a panel of the best: Sanam Loghavi from MD Anderson, Aaron Goodman UCSD, and David Steensma Novartis (formerly Farber/ Mayo) and VP #Real talk

Timothee Olivier joinrs me as we explore part 3 of the book Crossover, sample size, observational vs RCTs

Adam Cifu is here to discuss clinical excellence and his new podcast

T.O. joins me to grill me on the rest of Financial Conflict of Interest and Precision Oncology. We discuss the need for randomization, and when it can be omitted. A must listen for Oncology Fans.

VP discusses the LaceWing study in Blood. A Phase 3 RCT of GILT AZA vs AZA; Medical writers; confounding; table 1; balance; and so much more

Timothee Olivier joins me to discuss recent papers: IMPOWER10 Checkmate 816 Path CR/ EFS/ Surrogates Drug Dosing, cGCSF rules and more Bread and butter oncology